News & Updates

Among type 2 diabetes (T2D) patients with and without comorbid cardiovascular disease, those who have been newly initiated to glucagon-like peptide-1 receptor agonists (GLP-1RA) or sodium-glucose cotransporter 2 inhibitors (SGLT2i) appear to enjoy greater reductions in the risks of stroke and death when compared with new users of dipeptidyl peptidase-4 inhibitors (DPP-4i), suggests a study.

Nearly half of individuals with a newly diagnosed type 1 (T1D) or type 2 diabetes (T2D) suffer from gastrointestinal (GI) symptoms, according to a study presented at EASD 2023. These GI adverse events that are associated with glucose-lowering medications occur more frequently among those with already existing GI symptoms prior to treatment initiation.

In an analysis of over a million individuals in England, women aged <50 years had a markedly lower HbA1c distribution than men, suggesting that the application of the current HbA1c reference range may lead to underdiagnosis of type 2 diabetes (T2D) in premenopausal women.

Dapagliflozin reduced HbA_1c by 1.03 percentage points more than placebo in children and adolescents with type 2 diabetes (T2D), while saxagliptin showed no significant reduction vs placebo in the phase III T2NOW trial presented at EASD 2023.

In the subgroup analysis of the phase III FIGARO-DKD trial, the selective nonsteroidal mineralocorticoid receptor antagonist finerenone conferred cardiorenal benefits in Chinese patients with chronic kidney disease (CKD) and type 2 diabetes (T2D). The findings were consistent with that observed in the overall cohort.

Most adiposity markers are positively associated with incident type 2 diabetes (T2D), but waist to height ratio (WHtR) shows the most robust association and is a better predictor of T2D risk.

Moderate-to-vigorous physical activity (MVPA) in the morning appears to be more protective against obesity, particularly for individuals who are sedentary for most of the day, a study has found.

Genetic evidence confirms both the positive and negative associations of low-density lipoprotein cholesterol (LDL-C) reduction with certain metabolic and cardiovascular diseases (CVDs), according to the results of a Mendelian randomization (MR) study in the UK Biobank.